ARCHIVES

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

This article is from The Cancer Letter archive.

Vol. 21 No. 43 | November 10, 1995

Download PDF Visit The Full Archive

Related Articles

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

April 9, 2010

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

In Brief: ‘WSJ” Articles Call Attention To Problems With Cancer Program Knipmeyer to Leave NCI

May 19, 1989

More Surgical Patients Die When Nurse Caseloads Rise

November 29, 2002

Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.

November 14, 2003

NCI Contract Awards

November 1, 1996